- Home
- BDL vs OCUP Comparison
BDL vs OCUP Comparison
Compare BDL & OCUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDL
- OCUP
- Stock Information
- Founded
- BDL 1959
- OCUP 2018
- Country
- BDL United States
- OCUP United States
- Employees
- BDL N/A
- OCUP N/A
- Industry
- BDL Restaurants
- OCUP Biotechnology: Pharmaceutical Preparations
- Sector
- BDL Consumer Discretionary
- OCUP Health Care
- Exchange
- BDL Nasdaq
- OCUP Nasdaq
- Market Cap
- BDL 48.7M
- OCUP 53.1M
- IPO Year
- BDL N/A
- OCUP N/A
- Fundamental
- Price
- BDL $26.10
- OCUP $1.25
- Analyst Decision
- BDL
- OCUP Strong Buy
- Analyst Count
- BDL 0
- OCUP 3
- Target Price
- BDL N/A
- OCUP $18.67
- AVG Volume (30 Days)
- BDL 1.7K
- OCUP 90.1K
- Earning Date
- BDL 08-13-2024
- OCUP 11-11-2024
- Dividend Yield
- BDL 1.92%
- OCUP N/A
- EPS Growth
- BDL N/A
- OCUP N/A
- EPS
- BDL 1.64
- OCUP N/A
- Revenue
- BDL $185,457,000.00
- OCUP $16,449,000.00
- Revenue This Year
- BDL N/A
- OCUP N/A
- Revenue Next Year
- BDL N/A
- OCUP $258.69
- P/E Ratio
- BDL $15.93
- OCUP N/A
- Revenue Growth
- BDL 8.71
- OCUP N/A
- 52 Week Low
- BDL $24.43
- OCUP $1.15
- 52 Week High
- BDL $29.72
- OCUP $3.40
- Technical
- Relative Strength Index (RSI)
- BDL 45.95
- OCUP 44.19
- Support Level
- BDL $25.85
- OCUP $1.24
- Resistance Level
- BDL $26.41
- OCUP $1.39
- Average True Range (ATR)
- BDL 0.27
- OCUP 0.07
- MACD
- BDL -0.11
- OCUP -0.00
- Stochastic Oscillator
- BDL 29.29
- OCUP 22.22
About BDL Flanigan's Enterprises Inc.
Flanigan'S Enterprises Inc operates as a chain of small cocktail lounges and packages liquor stores throughout South Florida. Its menu consists of a wide variety of options including prime rib, steaks, pasta, entree salads, burgers, a variety of sandwiches, and oversized signature desserts. The business activity is principally conducted in two segments namely Restaurant and Package liquor store segment. Its Restaurant segment offers alcoholic beverages and full food service and Package stores consist of retail liquor sales and related items. The company generates maximum revenue from Restaurant segment.
About OCUP Ocuphire Pharma Inc.
Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting the front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.